Company Description
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders.
Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract.
The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia.
Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
| Country | United States |
| IPO Date | Dec 23, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Milton H. Werner Ph.D. |
Contact Details
Address: 3350 Riverwood Parkway Se, Suite 1900 Atlanta, Georgia 30339 United States | |
| Phone | 678-392-3419 |
| Website | inhibikase.com |
Stock Details
| Ticker Symbol | IKT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001750149 |
| CUSIP Number | 45719W106 |
| ISIN Number | US45719W2052 |
| Employer ID | 26-3407249 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Milton H. Werner Ph.D. | Chief Executive Officer, President and Director |
| Garth Lees-Rolfe | Chief Financial Officer |
| Dr. Roger Rush | Head of Preclinical Research |
| Dr. Surendra Singh | Head of Chemistry, Manufacturing and Controls |
| Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. | Chief Executive Officer of Clintrex Research Corporation and Member of Scientific Advisory Board |
| Dan Williams | Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2024 | 10-Q | Quarterly Report |
| May 15, 2024 | RW | Filing |
| May 9, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| May 9, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 30, 2024 | 8-K | Current Report |
| Apr 29, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 25, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |